Lunesta and Ingrowing nail - a phase IV clinical study of FDA data

Summary:

Ingrowing nail is reported as a side effect among people who take Lunesta (eszopiclone), especially for people who are female, 60+ old, have been taking the drug for 1 - 2 years also take Lortab, and have Osteoporosis.

The phase IV clinical study analyzes which people have Ingrowing nail when taking Lunesta. It is created by eHealthMe based on reports of 25,141 people who have side effects when taking Lunesta from the FDA, and is updated regularly.

What is Lunesta?

Lunesta has active ingredients of eszopiclone. It is often used in insomnia. eHealthMe is studying from 26,936 Lunesta users. Check the latest studies of Lunesta.

What is Ingrowing nail?

Ingrowing nail is found to be associated with 539 drugs and 408 conditions by eHealthMe. Check the latest studies of Ingrowing nail.

On Jul, 11, 2026

25,141 people reported to have side effects when taking Lunesta.
Among them, 27 people (0.11%) have Ingrowing nail.

Among these 27 people:

How long have people been on Lunesta when they have Ingrowing nail? *

What is the gender of people who have Ingrowing nail when taking Lunesta? *

female: 74.07 %
male: 25.93 %

What is the age of people who have Ingrowing nail when taking Lunesta? *

What are other drugs people take besides Lunesta? *

What are other side effects people have besides Ingrowing nail? *

Fatigue (feeling of tiredness): 22 people, 81.48%
Stress And Anxiety: 20 people, 74.07%
Hallucinations (sensations that appear real but are created by your mind): 16 people, 59.26%
Pain In Extremity: 16 people, 59.26%
Nausea (feeling of having an urge to vomit): 14 people, 51.85%
Swallowing Difficulty: 14 people, 51.85%
Nausea And Vomiting: 14 people, 51.85%
Muscle Spasms (muscle contraction): 14 people, 51.85%
Joint Pain: 14 people, 51.85%
Agitation (state of anxiety or nervous excitement): 13 people, 48.15%

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 9 people, 33.33%
Bone Loss: 5 people, 18.52%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 3 people, 11.11%
Mantle Cell Lymphoma Recurrent (cancer of lymphocytes, a type of white blood cell- recurrent): 3 people, 11.11%
Psychotic Disorder: 2 people, 7.41%
Back Pain: 2 people, 7.41%
Bipolar Disorder (mood disorder): 2 people, 7.41%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 3.70%
Breast Cancer Metastatic: 1 person, 3.70%
Cataplexy (loss of muscle tone accompanied by full conscious awareness): 1 person, 3.70%

* Approximation only. Some reports may have incomplete information.

Do you take Lunesta and have Ingrowing nail?

- Check whether Ingrowing nail is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lunesta:

Lunesta (26,936 reports)

Ingrowing nail treatments and more:

Ingrowing nail (3,607 reports)

Browse all side effects of Lunesta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ingrowing nail:

Ingrowing nail (539 drugs)

Browse all the conditions that are associated with Ingrowing nail:

Ingrowing nail (408 conditions)

Related publications that referenced our studies

Lai SW, Lai HC, Lin CL, Liao KF, "Zopiclone use associated with increased risk of acute pancreatitis: a case–control study in Taiwan", International journal of clinical practice, 2015 Nov .
Lai SW, Lai HC, Lin CL, Liao KF, "Zopiclone use associated with increased risk of acute pancreatitis: a case–control study in Taiwan", International journal of clinical practice, 2015 Nov .

How the study uses the data?

The study uses data from the FDA. It is based on eszopiclone (the active ingredients of Lunesta) and Lunesta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.